3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Myeloid
1
Conditions
Sarcoma
1
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Interventions
pembrolizumab
210
Cyclophosphamide
122
Nivolumab
109
Carboplatin
92
fludarabine
81
Gemcitabine
76
Specimen Handling
74
Bevacizumab
72
venetoclax
70
Injections
70
Magnetic Resonance Spectroscopy
67
Dexamethasone
66
Paclitaxel
64
Biopsy
59
atezolizumab
56
Cisplatin
53
Ipilimumab
50
Temozolomide
45
Docetaxel
42
Azacitidine
42
Pemetrexed
41
Lenalidomide
41
Oxaliplatin
40
Rituximab
39
Radiotherapy
39
Fluorouracil
39
Cetuximab
37
durvalumab
36
Cytarabine
36
Capecitabine
36
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
bexmarilimab
×
1 year
×
Clear all
NCT05428969
2026-04-23
BEXMAB
Faron Pharmaceuticals Ltd
Phase 1/2
Active not recruiting
181 enrolled
NCT07460986
2026-03-10
BEXAR
MedSIR
Phase 1/2
Not yet recruiting
278 enrolled